2402: Disease Classification

The Disease Classification (2402) Form is required for all transplants, including subsequent transplants (see below for more details) on the comprehensive report form track and cellular therapy infusions when the indication is malignant hematologic disorder, non-malignant disorder or solid tumor.

All transplant centers participating in the CIBMTR must submit a Disease Classification Form (Form 2402) for each allogeneic (related or unrelated) hematopoietic cell transplant (HCT). The Disease Classification Form is a requirement of the SCTOD for all United States transplant centers when either the stem cell donation or the transplant occurs within the United States. For more information regarding the SCTOD, see General Instructions, Stem Cell Therapeutics Outcomes Database.

Although data regarding recipients receiving autologous HCT are not required to be submitted as part of the C.W. Bill Young Transplant Program, the CIBMTR is highly committed to collecting data on these recipients for research studies. Centers choosing to report autologous data to the CIBMTR must report on all autologous transplants performed at their center. For more information regarding data reporting for autologous HCT, see General Instructions, Autologous Hematopoietic Stem Cell Transplant.

The Disease Classification Form may be submitted to the CIBMTR up to two weeks prior to the start of the recipient’s preparative regimen. This form is designed to capture important details regarding the recipient’s primary disease for which the reported HCT is being given. Key reporting areas differ depending on the disease reported, but may include disease type, subtype, transformations, cytogenetic and molecular markers, disease-specific laboratory results, staging, and disease status.

!Consent Status and Baseline Forms
There has been a change to the functionality of submitting the Pre-TED (2400), Disease Classification (2402), and Pre-Cellular Therapy Essential Data (4000) forms. If a consent status has not yet been reported for a recipient, the edit form icon will appear disabled (see Figure 1 below). When the user hovers over the icon, it will display that consent has not yet been reported for that recipient (see Figure 2 below). The user should go to the Consent Tool (see Navigation to the Consent Tool) and document the recipient’s consent status in order to enable the edit icon and allow for completion of the form.

Figure 1. Disabled Edit Form Icon

Figure 2. Hovered Text, Consent Not Yet Reported

Subsequent Infusions
Transplant centers must submit a Disease Classification (2402) form for all subsequent infusionns (excluding autologous rescues and allogeneic boosts, see below); this includes recipients assigned to the TED Forms and the Comprehensive Report Forms by the form selection algorithm.

For the majority of subsequent infusions, the recipient will remain on the original follow-up form track (TED or CRF) assigned by the form selection algorithm. For more information regarding center type and the form selection algorithm, see General Instructions, Center Type and Data Collection Forms. A recipient may need to change tracks if enrolled in a study that requires comprehensive forms.

If the recipient receives an autologous HCT as a result of a poor graft or graft failure or an allogeneic infusion using a prior donor for poor graft function / insufficient donor chimerism, the form sequence will not start over again. Generally, these types of infusions (autologous rescue and allogeneic boosts) are used to treat the recipient’s poor graft response, rather than to treat the recipient’s disease. The Indication for CIBMTR Data Reporting (2814) will come due for both autologous rescues and allogeneic boosts; however, after completing the form, the Donor Cellular Infusion (2199) will come only come due for allogeneic boosts.

For recipients of multiple transplants, completing the Indication for CIBMTR Data Reporting (2814) for the subsequent HCT will make the Pre-TED (2400) come due.

Links to Sections of the Form
Q1 – 2: Primary Disease for HCT
Q3 – 127: Acute Myelogenous Leukemia
Q128 – 194: Acute Lymphoblastic Leukemia
Q195 – 301: Acute Leukemias of Mixed or Ambiguous Lineage
Q302 – 308: Chronic Myelogenous Leukemia
Q309 – 378: Myelodysplastic Diseases
Q379 – 479: Myeloproliferative Diseases
Q480 – 483: Other Leukemia
Q484 – 500: Hodgkin and Non-Hodgkin Lymphoma
Q501 – 558: Multiple Myeloma / Plasma Cell Disorder
Q559 – 561: Solid Tumors
Q562 – 564: Severe Aplastic Anemia
Q565: Inherited Bone Marrow Failure Syndromes
Q566 – 599: Hemoglobinopathies
Q600: Paroxysmal Nocturnal Hemoglobinuria
Q601 – 608: Inborn Errors of Immunity
Q609 – 610: Inherited Abnormalities of Platelets
Q611 – 613: Inherited Disorders of Metabolism
Q614 – 619: Histiocytic Disorders
Q620 – 623: Autoimmune Diseases
Q624 – 625: Tolerance Induction Associated with Solid Organ Transplant
Q626: Other Disease

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

If you need to reference the historical Manual Change History for this form, review the table below or reference the retired manual section on the Retired Forms Manuals webpage.

Date	Manual Section	Add/Remove/Modify	Description
10/24/2025	2402: Disease Classification	Modify	Version 10 of the 2402: Pre-TED Disease Classification section of the Forms Instructions Manual released. Version 10 corresponds to revision 10 of the Form 2402.

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.